Post-treatment sarcoma in breast cancer patients
Identifieur interne : 004A05 ( Istex/Corpus ); précédent : 004A04; suivant : 004A06Post-treatment sarcoma in breast cancer patients
Auteurs : Mary S. Brady ; Carol F. Garfein ; Jeanne A. Petrek ; Murray F. BrennanSource :
- Annals of Surgical Oncology [ 1068-9265 ] ; 1994-01-01.
Abstract
Abstract: Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years. Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation). Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98). Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.
Url:
DOI: 10.1007/BF02303543
Links to Exploration step
ISTEX:9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Post-treatment sarcoma in breast cancer patients</title><author><name sortKey="Brady, Mary S" sort="Brady, Mary S" uniqKey="Brady M" first="Mary S." last="Brady">Mary S. Brady</name><affiliation><mods:affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Garfein, Carol F" sort="Garfein, Carol F" uniqKey="Garfein C" first="Carol F." last="Garfein">Carol F. Garfein</name><affiliation><mods:affiliation>Mt. Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Petrek, Jeanne A" sort="Petrek, Jeanne A" uniqKey="Petrek J" first="Jeanne A." last="Petrek">Jeanne A. Petrek</name><affiliation><mods:affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Brennan, Murray F" sort="Brennan, Murray F" uniqKey="Brennan M" first="Murray F." last="Brennan">Murray F. Brennan</name><affiliation><mods:affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1007/BF02303543</idno><idno type="url">https://api.istex.fr/document/9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004A05</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004A05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Post-treatment sarcoma in breast cancer patients</title><author><name sortKey="Brady, Mary S" sort="Brady, Mary S" uniqKey="Brady M" first="Mary S." last="Brady">Mary S. Brady</name><affiliation><mods:affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Garfein, Carol F" sort="Garfein, Carol F" uniqKey="Garfein C" first="Carol F." last="Garfein">Carol F. Garfein</name><affiliation><mods:affiliation>Mt. Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Petrek, Jeanne A" sort="Petrek, Jeanne A" uniqKey="Petrek J" first="Jeanne A." last="Petrek">Jeanne A. Petrek</name><affiliation><mods:affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Brennan, Murray F" sort="Brennan, Murray F" uniqKey="Brennan M" first="Murray F." last="Brennan">Murray F. Brennan</name><affiliation><mods:affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Surgical Oncology</title><title level="j" type="abbrev">Annals of Surgical Oncology</title><idno type="ISSN">1068-9265</idno><idno type="eISSN">1534-4681</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>New York</pubPlace><date type="published" when="1994-01-01">1994-01-01</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="66">66</biblScope><biblScope unit="page" to="72">72</biblScope></imprint><idno type="ISSN">1068-9265</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1068-9265</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years. Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation). Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98). Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.</div></front></TEI><istex><corpusName>springer</corpusName><keywords><teeft><json:string>sarcoma</json:string><json:string>lymphangiosarcoma</json:string><json:string>radiotherapy</json:string><json:string>breast cancer</json:string><json:string>mastectomy</json:string><json:string>nonlymphangiosarcoma</json:string><json:string>other types</json:string><json:string>lymphedema</json:string><json:string>oncol</json:string><json:string>nonlymphangiosarcoma sarcoma</json:string><json:string>radical mastectomy</json:string><json:string>surg</json:string><json:string>other sarcomas</json:string><json:string>median</json:string><json:string>survivor</json:string><json:string>soft tissue</json:string><json:string>significant difference</json:string><json:string>antecedent breast cancer</json:string><json:string>carcinoma</json:string><json:string>antecedent</json:string><json:string>breast cancer patients</json:string><json:string>breast conservation</json:string><json:string>family history</json:string><json:string>surg oncol</json:string><json:string>survival analysis</json:string><json:string>extremity</json:string><json:string>evaluable patients</json:string><json:string>memorial cancer center</json:string><json:string>desmoid tumors</json:string><json:string>median interval</json:string><json:string>tumor grade</json:string><json:string>bone sarcoma</json:string><json:string>survival distribution</json:string><json:string>adjuvant radiotherapy</json:string><json:string>breast</json:string></teeft></keywords><author><json:item><name>Dr. Mary S. Brady MD</name><affiliations><json:string>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Carol F. Garfein MBA</name><affiliations><json:string>Mt. Sinai School of Medicine, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Jeanne A. Petrek MD</name><affiliations><json:string>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Murray F. Brennan MD</name><affiliations><json:string>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</json:string></affiliations></json:item></author><articleId><json:string>BF02303543</json:string><json:string>Art11</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years. Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation). Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p>0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98). Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.</abstract><qualityIndicators><score>6.455</score><pdfWordCount>3455</pdfWordCount><pdfCharCount>21575</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>252</abstractWordCount><abstractCharCount>1738</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Post-treatment sarcoma in breast cancer patients</title><genre><json:string>research-article</json:string></genre><host><title>Annals of Surgical Oncology</title><language><json:string>unknown</json:string></language><publicationDate>1994</publicationDate><copyrightDate>1994</copyrightDate><issn><json:string>1068-9265</json:string></issn><eissn><json:string>1534-4681</json:string></eissn><journalId><json:string>10434</json:string></journalId><volume>1</volume><issue>1</issue><pages><first>66</first><last>72</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Surgery</value></json:item><json:item><value>Oncology</value></json:item><json:item><value>Surgical Oncology</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>surgery</json:string><json:string>oncology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>oncology & carcinogenesis</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>1994</publicationDate><copyrightDate>1994</copyrightDate><doi><json:string>10.1007/BF02303543</json:string></doi><id>9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Post-treatment sarcoma in breast cancer patients</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Springer-Verlag</publisher><pubPlace>New York</pubPlace><availability><p>The Society of Surgical Oncology, Inc., 1994</p></availability><date>1993-03-30</date></publicationStmt><notesStmt><note>Original Articles</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Post-treatment sarcoma in breast cancer patients</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Mary</forename><surname>Brady</surname></persName><roleName type="degree">Dr.</roleName><affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Carol</forename><surname>Garfein</surname></persName><roleName type="degree">MBA</roleName><note type="biography">medical student</note><affiliation>medical student</affiliation><affiliation>Mt. Sinai School of Medicine, New York, New York, USA</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Jeanne</forename><surname>Petrek</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Murray</forename><surname>Brennan</surname></persName><roleName type="degree">MD</roleName><affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</affiliation></author><idno type="istex">9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7</idno><idno type="DOI">10.1007/BF02303543</idno><idno type="ArticleID">BF02303543</idno><idno type="ArticleID">Art11</idno></analytic><monogr><title level="j">Annals of Surgical Oncology</title><title level="j" type="abbrev">Annals of Surgical Oncology</title><idno type="pISSN">1068-9265</idno><idno type="eISSN">1534-4681</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">15</idno><idno type="volume-issue-count">6</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>New York</pubPlace><date type="published" when="1994-01-01"></date><biblScope unit="volume">1</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="66">66</biblScope><biblScope unit="page" to="72">72</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993-03-30</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years. Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation). Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98). Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Surgery</term></item><item><term>Oncology</term></item><item><term>Surgical Oncology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1993-03-30">Created</change><change when="1994-01-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>New York</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>10434</JournalID><JournalPrintISSN>1068-9265</JournalPrintISSN><JournalElectronicISSN>1534-4681</JournalElectronicISSN><JournalTitle>Annals of Surgical Oncology</JournalTitle><JournalAbbreviatedTitle>Annals of Surgical Oncology</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Surgery</JournalSubject><JournalSubject Type="Secondary">Oncology</JournalSubject><JournalSubject Type="Secondary">Surgical Oncology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>1</VolumeIDStart><VolumeIDEnd>1</VolumeIDEnd><VolumeIssueCount>6</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>1</IssueIDStart><IssueIDEnd>1</IssueIDEnd><IssueArticleCount>15</IssueArticleCount><IssueHistory><CoverDate><Year>1994</Year><Month>1</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>The Society of Surgical Oncology, Inc.</CopyrightHolderName><CopyrightYear>1994</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art11"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>BF02303543</ArticleID><ArticleDOI>10.1007/BF02303543</ArticleDOI><ArticleSequenceNumber>11</ArticleSequenceNumber><ArticleTitle Language="En">Post-treatment sarcoma in breast cancer patients</ArticleTitle><ArticleCategory>Original Articles</ArticleCategory><ArticleFirstPage>66</ArticleFirstPage><ArticleLastPage>72</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2006</Year><Month>1</Month><Day>7</Day></RegistrationDate><Received><Year>1993</Year><Month>3</Month><Day>30</Day></Received><Accepted><Year>1993</Year><Month>7</Month><Day>21</Day></Accepted></ArticleHistory><ArticleCopyright><CopyrightHolderName>The Society of Surgical Oncology, Inc.</CopyrightHolderName><CopyrightYear>1994</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>10434</JournalID><VolumeIDStart>1</VolumeIDStart><VolumeIDEnd>1</VolumeIDEnd><IssueIDStart>1</IssueIDStart><IssueIDEnd>1</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><Prefix>Dr.</Prefix><GivenName>Mary</GivenName><GivenName>S.</GivenName><FamilyName>Brady</FamilyName><Degrees>MD</Degrees></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Carol</GivenName><GivenName>F.</GivenName><FamilyName>Garfein</FamilyName><Degrees>MBA</Degrees></AuthorName><Role>medical student</Role></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Jeanne</GivenName><GivenName>A.</GivenName><FamilyName>Petrek</FamilyName><Degrees>MD</Degrees></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Murray</GivenName><GivenName>F.</GivenName><FamilyName>Brennan</FamilyName><Degrees>MD</Degrees></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>From the Department of Surgery</OrgDivision><OrgName>Memorial Sloan-Kettering Cancer Center</OrgName><OrgAddress><City>New York</City><State>New York</State><Country>USA</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgName>Mt. Sinai School of Medicine</OrgName><OrgAddress><City>New York</City><State>New York</State><Country>USA</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Abstract</Heading><Para><Emphasis Type="Bold">Background:</Emphasis> Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years.</Para><Para><Emphasis Type="Bold">Methods:</Emphasis> In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation).</Para><Para><Emphasis Type="Bold">Results:</Emphasis> Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98).</Para><Para><Emphasis Type="Bold">Conclusions:</Emphasis> Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.</Para></Abstract><KeywordGroup Language="En"><Heading>Key Words</Heading><Keyword>Sarcoma</Keyword><Keyword>Breast cancer</Keyword><Keyword>Radiation</Keyword><Keyword>Lymphangiosarcoma</Keyword></KeywordGroup><ArticleNote Type="PresentedAt"><SimplePara>Presented at the 46th Annual Cancer Symposium of the Society of Surgical Oncology, Los Angeles, March 18–21, 1993.</SimplePara></ArticleNote></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Post-treatment sarcoma in breast cancer patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Post-treatment sarcoma in breast cancer patients</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="termsOfAddress">Dr.</namePart><namePart type="given">Mary</namePart><namePart type="given">S.</namePart><namePart type="family">Brady</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carol</namePart><namePart type="given">F.</namePart><namePart type="family">Garfein</namePart><namePart type="termsOfAddress">MBA</namePart><affiliation>Mt. Sinai School of Medicine, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role><description>medical student</description></name><name type="personal"><namePart type="given">Jeanne</namePart><namePart type="given">A.</namePart><namePart type="family">Petrek</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Murray</namePart><namePart type="given">F.</namePart><namePart type="family">Brennan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">New York</placeTerm></place><dateCreated encoding="w3cdtf">1993-03-30</dateCreated><dateIssued encoding="w3cdtf">1994-01-01</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Abstract: Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years. Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation). Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98). Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.</abstract><note>Original Articles</note><relatedItem type="host"><titleInfo><title>Annals of Surgical Oncology</title></titleInfo><titleInfo type="abbreviated"><title>Annals of Surgical Oncology</title></titleInfo><genre type="journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1994-01-01</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Surgery</topic><topic>Oncology</topic><topic>Surgical Oncology</topic></subject><identifier type="ISSN">1068-9265</identifier><identifier type="eISSN">1534-4681</identifier><identifier type="JournalID">10434</identifier><identifier type="IssueArticleCount">15</identifier><identifier type="VolumeIssueCount">6</identifier><part><date>1994</date><detail type="volume"><number>1</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="pages"><start>66</start><end>72</end></extent></part><recordInfo><recordOrigin>The Society of Surgical Oncology, Inc., 1994</recordOrigin></recordInfo></relatedItem><identifier type="istex">9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7</identifier><identifier type="DOI">10.1007/BF02303543</identifier><identifier type="ArticleID">BF02303543</identifier><identifier type="ArticleID">Art11</identifier><accessCondition type="use and reproduction" contentType="copyright">The Society of Surgical Oncology, Inc., 1994</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>The Society of Surgical Oncology, Inc., 1994</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 004A05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7
|texte= Post-treatment sarcoma in breast cancer patients
}}
| This area was generated with Dilib version V0.6.31. |  |